Partying Like It's 1999

Here we go again. With pharma companies partying like it's 1999, Biospace has launched a handy new tool for tracking M&A in the bio-pharma industry. Billions and billions bought!

"After a slow 2022 and early part of 2023, the pace of mergers and acquisitions in the pharmaceutical and biotech sectors has accelerated since the middle of last year, highlighted by Pfizer’s $43 billion takeover of Seagen. Since the calendar turned to 2024, we have seen some blockbusters, including Novo Nordisk's $16.5 billion purchase agreement for Catalent and the closing of Bristol Myers Squibb's $4.8 billion acquisition of Mirati Therapeutics and $14 billion takeover of Karuna Therapeutics."

#Pharma #DrugMergers #5ForcesofHCT #HCTConsolidation